Print pageHome » Register For Stevens Institute of Technology's Fall 2010 Semester
Register For Stevens Institute of Technology's Fall 2010 Semester
PharmaManufacturing.com
08/13/2010
Stevens Institute of Technology's Fall 2010 semester is right around the corner! If you haven’t yet, there is still time to apply for a program or just enroll for classes as a non-matriculating student.
You can view the list of all courses available for Fall 2010 here.
Register now for the Fall 2010 WebCampus semester!.
-Classes start the week of September 7, 2010.
With over 250 instructor-led courses, the WebCampus program offers you a convenient and flexible way to earn an MBA in Technology Management, or any of 17 Masters Degrees or over 70 Graduate Certificates completely online.
Offering maximum flexibility for professionals, you can access your WebCampus courses from home or while traveling, any time, day or night. Online courses offer you the perfect balance of convenience and academic rigor, as they cover the same material and are conducted by the same faculty as Stevens conventional courses.
Detailed course and program descriptions, as well as admission information can be obtained at the WebCampus home page.
Students who are members of Putman receive a 10% rebate when they enroll in WebCampus courses. Students do not have to be accepted into a program in order to take graduate classes at Stevens. It is possible to take up to three (3) classes as a non-matriculating student while your application is under review.
REGISTRATION IS OPEN! ENROLL NOW! STEVENS ONLINE CLASSES START THE WEEK OF SEPTEMBER 7, 2010!
Students who are subscribers of Putman receive a 10% rebate when they enroll in WebCampus courses. Students do not have to be accepted into a program in order to take graduate classes at Stevens. It is possible to take up to three (3) classes as a non-matriculating student while your application is under review. For more on this or if you have any further questions, please do not hesitate to contact the WebCampus Division at webcampus@stevens.edu, or (201) 216-5092.
More News:
-
02/09/2012
Watchdog Fines Ernst & Young $2 million Over Medicis Pharma Corp. AuditsFrom Reuters.com
The watchdog board for corporate auditors on Wednesday said it has imposed a $2 million penalty, its largest fine ever, on accounting and consulting firm Ernst & Young LLP in a settlement involving past audits of Medicis Pharmaceutical Corp.
-
02/09/2012
FDA Issues Draft Guidance on Biosimilar Product Development
The U.S. Food and Drug Administration today issued three draft guidance documents on biosimilar product development to assist industry in developing such products in the United States.
-
02/08/2012
Biomedical Industry Loses Momentum in California, According to 2012 Report
Innovation slows as productivity in the Biomedical industry declines
-
02/02/2012
Pfizer Baby Boom? Pfizer's Official StatementFrom Pharmalot.com
About nine months from now, a new phenomenon may appear at a hospital near you: the Pfizer baby. Why? The drugmaker has taken the embarrassing step of recalling 1 million packets of birth control pills due to a packaging error. Hear EVP and CMO, Freda Lewis-Hall's read Pfizer's official statement.
-
02/02/2012
News: AstraZeneca To Cut 7,300 JobsFrom MarketWatch.com
Drug firm AstraZeneca on Thursday said it would cut approximately 7,300 jobs as part of an ongoing initiative to reduce costs and drive innovation.
-
02/01/2012
Pfizer Recalls 1 Million Birth Control Packs for Error That Could Cause Unintended PregnancyFrom WashingtonPost.com
Pfizer Inc. is recalling 1 million packets of birth control pills due to a packaging error that could raise the risk of an accidental pregnancy by leaving women with an inadequate dose. The problem affects 14 lots of Lo/Ovral-28 tablets and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets. Both products are manufactured by Pfizer and marketed in the U.S. by Akrimax Rx Products under the Akrimax Pharmaceuticals brand.
-
01/26/2012
News: Abbott Labs Cuts 700 Manufacturing JobsFrom WashingtonPost.com
Medical device and drugmaker Abbott Laboratories said Wednesday it will lay off 700 employees as part of ongoing restructuring efforts. A company spokeswoman said most of the layoffs will affect employees who manufacture the company’s heart stents and diagnostic tests.
- 01/24/2012 ISPE Announces 2012 FOYA Winners
- 01/24/2012 Genzyme Gains Approval for Framingham Site, a Boost to Fabrazyme Production
-
01/19/2012
Big Pharma Execs May Wish They'd Never Heard Of Paula DeenFrom Forbes.com
Novo Nordisk has nabbed Paula Deen as a new spokeswoman to help raise awareness about type 2 diabetes. Many in the drug industry wish it weren’t so, but without major legal and regulatory changes, such matches between celebs and drug firms are as certain as the sun rising in the east.
- All news »
Get Connected Now!
- Featured White Papers
Sponsored Links
